Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyAloha Care denosumab coverage & Prior Auth | OpenP…
    Ask Trek AI about this page
    ModifiedAloha CarePolicy RXMP-39

    Denosumab (Xgeva/Prolia and biosimilars) Medicare coverage criteria

    Customize your policy alerts

    Sign up for Aloha Care Policy RXMP-39 alerts

    Get alerted when Policy RXMP-39 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare (and Medicaid) prior authorization, quantity limits, preferred biosimilars, and clinical approval/renewal criteria for denosumab products (Xgeva/Prolia and listed biosimilars) provided under Aloha Care Medicare benefit.

    Policy Summary
    PayerAloha Care
    PolicyDenosumab (Xgeva/Prolia and biosimilars) Medicare coverage criteria
    Policy CodePolicy RXMP-39
    Change TypeAdopted external guidance (Optum Health)
    Effective DateJan 1, 2026
    Last ReviewDec 6, 2025
    Next Review Date
    Key ActionSubmit prior authorization for denosumab products; approvals issued for up to 12 months and preferred biosimilars should be tried before non-preferred agents where required.
    SourceLink
    POLICY UPDATE CHANGES

    Adopt Optum Health's Denosumab and Biosimilars, Cancer Related Indications, 12/5/2025.

    1 yearauthorization length (initial/renewal)
    90 daysMedicare Part B transition
    Wyost, Osenveltpreferred biosimilars named
    2 agentsnon-preferred trial/failure rule

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    J0897HCPCS code referenced

    Coverage and Medical Necessity Criteria

    Medicare/Medicaid denosumab approval criteria

    Clinical approval and renewal criteria for Xgeva and denosumab biosimilars for listed oncology and bone indications.

    Covered indications include hypercalcemia of malignancy; giant cell tumor of bone; prevention of skeletal-related events in multiple myeloma or bone metastasis from solid tumors.
    For new starts of Xgeva or a denosumab biosimilar: inadequate response to or contraindication to an injectable bisphosphonate (e.g., pamidronate, zoledronic acid) AND trial/failure of a preferred biosimilar (examples listed: Osenvelt or Wyost).

    Step therapy requirement applies except during Medicare 90-day transition for new members.

    Non-preferred agent rule: non-preferred denosumab products require trial and failure of 2 preferred agents from each drug class; if only one preferred agent exists, failure of one preferred agent is sufficient.
    Authorization length: initial and renewal approvals are for no more than 12 months (authorization required).
    Dosing must be in accordance with United States Food and Drug Administration approved labeling.
    Renewal requires documentation of positive clinical response to therapy and continued relevant systemic therapy when applicable (see indication-specific nodes).

    Cancer-related indications criteria

    Initial and renewal coverage criteria by indication

    Breast cancer (adjuvant/with aromatase inhibitor context): Diagnosis of breast cancer; member is receiving aromatase inhibitor therapy; history of intolerance to oral bisphosphonate OR failure/contraindication/intolerance to IV bisphosphonate; dosing per FDA labeling; authorization up to 12 months.
    Multiple myeloma with bone involvement: Diagnosis of multiple myeloma or presence of metastatic bone disease; member has expected survival ≥ 3 months; refractory/contraindication/intolerance to IV bisphosphonate therapy (e.g., pamidronate, zoledronic acid); dosing per FDA labeling; authorization up to 12 months.
    Giant cell tumor of bone: Member >18 years of age or skeletally mature adolescent; diagnosis of localized, recurrent or metastatic giant cell tumor of bone; disease is unresectable or surgical resection likely to result in severe morbidity; dosing per FDA labeling; authorization up to 12 months.
    Hypercalcemia of malignancy: Diagnosis defined as albumin-corrected serum calcium > 12.5 mg/dL (3.1 mmol/L); refractory/contraindication/intolerance to IV bisphosphonates within the last 30 days; dosing per FDA labeling; authorization up to 12 months.

    Renewal for ADT-associated bone loss

    Renewal and indication-related criteria excerpts and contextual clinical thresholds drawn from the policy text in this segment.

    ALL of the following

    • Member is receiving androgen deprivation therapy.
    • Documentation of positive clinical response to therapy.
    • Dosing is in accordance with United States Food and Drug Administration approved labeling.
    • Authorization is limited to no more than 12 months.

    Coverage and clinical criteria summary

    Coverage considerations reference FDA-labeled indications and NCCN guideline recommendations; Medicare may cover Part B-administered denosumab when furnished incident to a physician's service and when consistent with benefit rules.

    FDA-labeled cancer indications: Xgeva is indicated for prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma; treatment of unresectable giant cell tumor of bone in adults and skeletally mature adolescents; and treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
    Prolia labeling and bone-mass indications: Prolia is indicated to increase bone mass in postmenopausal women and men at high risk for fracture and for prevention of bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer, among other labeled uses.
    NCCN guidance: denosumab is recommended across multiple malignancy-related bone indications (giant cell tumor of bone, breast cancer bone metastasis, kidney cancer bone metastases, multiple myeloma, non-small cell lung cancer bone metastases, castration-resistant prostate cancer with bone metastases, systemic mastocytosis-related bone disease, thyroid carcinoma bone metastases) with varying recommendation categories (1 or 2A).
    Medicare coverage context: There is no denosumab-specific NCD; refer to applicable LCDs/LCAs for bisphosphonates and drugs/biologics. Medicare may cover outpatient (Part B) drugs furnished 'incident to' a physician's service when drugs are not usually self-administered.

    Cancer-related indications (ICD-10 mappings)

    Lists cancer-related diagnoses and ICD-10 codes that map to denosumab and biosimilar coverage considerations.

    Representative cancer-related diagnoses and ICD-10 mappings include: C61 (Malignant neoplasm of prostate); C79.51 (Secondary malignant neoplasm of bone); C79.52 (Secondary malignant neoplasm of bone marrow); C90.00 (Multiple myeloma not having achieved remission).

    Policy includes additional C79.x secondary malignancy codes (see code list).

    Indication groupings and criteria shortcuts

    Criteria shortcuts and indication groupings are listed to simplify review for commonly requested oncology and bone indications.

    Indication groupings/shortcuts include: non-metastatic prostate cancer (initial and renewal), breast cancer (initial and renewal), multiple myeloma with bone metastases (initial and renewal), giant cell tumor of bone, hypercalcemia of malignancy, castration-resistant prostate cancer with bone metastases, and systemic mastocytosis with bone pain.

    Initial Authorization Requirements

    Initial therapy criteria

    Initial authorization requirements

    Preferred agent may be approved if criteria are met; for non-preferred agents, the member must have tried and failed 2 preferred agents from each drug class (or 1 if only one preferred exists).
    Prior bisphosphonate requirement: history of intolerance to oral bisphosphonate therapy; OR history of failure, contraindication, or intolerance to intravenous (IV) bisphosphonate therapy (e.g., pamidronate, zoledronic acid).
    Dosing requirement: dosing must follow FDA-approved labeling.
    Authorization length: initial authorization is for up to 12 months.

    Initial therapy criteria

    Initial criteria common elements

    Renewal and Continuation Requirements

    Renewal/Continuation criteria — Renewal requirements

    Renewal/continuation requests are approved only when ALL of the following renewal conditions are met:

    ALL of the following

    • Member is receiving appropriate disease-specific systemic therapy (e.g., androgen deprivation therapy for prostate cancer) and documentation of ongoing therapy is provided
    • Documentation of positive clinical response to therapy is submitted (clinical assessment or objective evidence)
    • Dosing is in accordance with United States FDA–approved labeling for the requested denosumab product
    • Authorization/approval length for the renewal request is for no more than 12 months

    Billing Codes and Diagnosis Mapping

    Denosumab and biosimilarsHCPCSCovered
    J0897Injection, denosumab, 1 mg (Prolia/Xgeva)
    C9399Injection, denosumab-nxxp (Bildyos/Bilprevda), biosimilar, 1 mg
    Q5158Injection, denosumab-bhntz (Conexxence/Bomyntra), biosimilar, 1 mg
    Q5136Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg (preferred)
    Q5157Injection, denosumab-bmwo (Stoboclo/Osenvelt), biosimilar, 1 mg (preferred)
    Q5159Injection, denosumab-dssb (Ospomyv/Xbryk), biosimilar, 1 mg
    Products listedNDC
    No codes listed
    HCPCS and biosimilar codesHCPCS
    J0897Injection, denosumab, 1 mg (Prolia and Xgeva)
    Q5136Injection, denosumab-bbdz, 1 mg (biosimilar)
    Q5157Injection, denosumab-bmwo, 1 mg (biosimilar)
    Q5158Injection, denosumab-bnht, 1 mg (biosimilar)
    Q5159Injection, denosumab-dssb, 1 mg (biosimilar)
    Illustrative diagnosis codesICD-10
    M81.8Other osteoporosis without current pathological fracture
    M80.811AOther osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture
    Sample ICD-10 codes referencedICD-10Covered
    M80.839AOther osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture
    M80.839DOther osteoporosis with current pathological fracture, unspecified forearm, subsequent encounter for fracture with routine healing
    M80.841AOther osteoporosis with current pathological fracture, right hand, initial encounter for fracture
    M80.851AOther osteoporosis with current pathological fracture, right femur, initial encounter for fracture
    M80.88XAOther osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture
    Z78.310Personal history of (healed) osteoporosis fracture
    C61Malignant neoplasm of prostate
    C79.51Secondary malignant neoplasm of bone
    C79.52Secondary malignant neoplasm of bone marrow
    C90.00Multiple myeloma not having achieved remission

    Prior Authorization, Documentation, and Operational Guidance

    Prior Authorization

    Prior authorization and coding required

    Prior authorization is required for denosumab products (HCPCS J0897 and listed biosimilar Q-codes); Medicare/Medicaid preferred biosimilars include Wyost and Osenvelt. Authorization/coverage decisions reference these codes and preferred status.

    • HCPCS: J0897 (denosumab) and biosimilar Q-codes (Q5136, Q5157, Q5158, Q5159) listed
    • Medicare/Medicaid preferred agents: Wyost or Osenvelt
    Documentation Required

    Medicare Part B 90-day transition: exemptions for active treatment

    A 90-day Medicare Part B transition period applies for new Medicare members on an active course of treatment; during those 90 days Coverage and Step Therapy requirements do not apply. After 90 days, policy criteria must be met for continued coverage.

    • Transition period: first 90 days of Medicare enrollment

    Key Terms and Definitions

    LCD/NCD/LCA — Medicare Part B coverage review
    DefinitionMedicare Part B coverage review using applicable Local Coverage Determination (LCD), National Coverage Determination (NCD), or Local Coverage Article (LCA) for the Hawaii region; no LCD/NCD/LCA found as of 10/25/2025 — internal criteria provided.
    ReferenceSearch LCD/NCD/LCA at the CMS Medicare Coverage Database: https://www.cms.gov/medicare-coverage-database/search.aspx.
    Actionable noteWhen determining Part B applicability for denosumab, confirm whether the drug is furnished 'incident to' a physician service and whether it is usually self-administered (see Medicare Benefit Policy Manual Chapter 15, Section 50).
    Policy statusUpdated 12/6/2025; effective 1/1/2026 (Policy RXMP-39).
    Skeletally mature adolescent — definition
    Definition

    Step Therapy and Trial Requirements

    RuleDetails
    Step-therapy applies for new starts
    For denosumab (Xgeva) and biosimilars, step-therapy is required for new starts except during the Medicare Part B 90-day transition period for new members; members on an active course of treatment during the first 90 days are not subject to step therapy
    Preferred-agent-first requirement
    A preferred biosimilar (examples: Osenvelt or Wyost) may be approved if the member meets clinical criteria; new starts must try preferred agents first per policy
    Prior therapy requirement
    New-start denosumab requires inadequate response to or contraindication to an injectable bisphosphonate (e.g., pamidronate, zoledronic acid) AND trial/failure of one of the preferred biosimilars (e.g., Osenvelt or Wyost)
    RequirementPolicy detail
    Trial and failure prior to non-preferred approval
    For non-preferred denosumab products, the member must have tried and failed 2 preferred agents from each drug class; if only one preferred agent exists, failure of that one preferred agent is sufficient
    Age / population applicability
    Applies across indicated populations (e.g., adults or skeletally mature adolescents where specified); preferred/non-preferred rules are included in initial criteria for all indications
    Documentation of bisphosphonate intolerance/failure
    Where indicated (e.g., hypercalcemia of malignancy, systemic mastocytosis), documentation of refractory/contraindication/intolerance to IV bisphosphonates within the prior 30 days is required as part of the approval pathway for non-preferred agents

    Quantity Limits and Dosing Examples

    Denosumab injectable products / bisphosphonates (examples)
    Examples — denosumab dosingProlia dosing for osteoporosis/ADT-related bone loss: 60 mg subcutaneous every 6 months; Xgeva dosing for prevention of SREs in metastatic cancer: 120 mg subcutaneous every 4 weeks.
    Bisphosphonate examples (comparative/prior therapy)Reclast (zoledronic acid) 5 mg every 365 days; Boniva (ibandronate) injection dosing per schedule (e.g., J1740 3mg/3mL every 90 days).
    Quantity limitsQuantity limits and dosing frequency vary by HCPCS; prior authorization duration typically up to 1 year.
    Billing Rule

    Infusion center administration and Part B billing

    Preferred Agents and Biosimilar Coding

    Billing Rule

    Preferred biosimilars for Medicare/Medicaid

    For Medicare and Medicaid reviews, Xgeva (denosumab) and listed biosimilars (including Wyost and Osenvelt) are identified as preferred agents for cancer-related indications.

    • Preferred biosimilars named: Wyost, Osenvelt
    • Products listed: Bilprevda, Bomyntra, Osenvelt (preferred), Wyost (preferred), Xgeva, Xbryk
    Billing Rule

    Use preferred denosumab products when meeting criteria

    Xgeva and several biosimilars are enumerated as preferred products for cancer-related indications; providers should use preferred biosimilars when criteria are met to support coverage.

    • HCPCS/Q-codes listed for denosumab and biosimilars (see policy code table)
    • Using preferred biosimilars supports approval when criteria are satisfied
    Billing Rule
    Policy Summary
    PayerAloha Care
    PolicyDenosumab (Xgeva/Prolia and biosimilars) Medicare coverage criteria
    Policy CodePolicy RXMP-39
    Change TypeAdopted external guidance (Optum Health)
    Effective DateJan 1, 2026
    Last ReviewDec 6, 2025
    Next Review Date
    Key ActionSubmit prior authorization for denosumab products; approvals issued for up to 12 months and preferred biosimilars should be tried before non-preferred agents where required.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaInitial Authorization RequirementsRenewal and Continuation RequirementsBilling Codes and Diagnosis MappingPrior Authorization, Documentation, and Operational GuidanceKey Terms and DefinitionsStep Therapy and Trial RequirementsQuantity Limits and Dosing ExamplesPreferred Agents and Biosimilar Coding
    Castration-resistant prostate cancer with metastatic bone disease: Diagnosis of castration-resistant prostate cancer with metastatic bone disease; dosing per FDA labeling; authorization up to 12 months.
    Systemic mastocytosis with bone pain: Diagnosis of systemic mastocytosis with bone pain and diagnosis of osteoporosis or osteopenia; refractory/contraindication/intolerance to IV bisphosphonates (past 30 days); dosing per FDA labeling; authorization up to 12 months.
    Clinical trial evidence: In a phase 3 trial of men with castration-resistant prostate cancer naive to IV bisphosphonates (n=1904), denosumab delayed median time to first SRE compared with zoledronic acid (20.7 vs 17.1 months; HR 0.82).
    Preferred agent may be approved if criteria are met; non-preferred agents require specified trial/failure of preferred agents.
    Age criteria where specified: member ≥ 18 years or a skeletally mature adolescent (defined by presence of at least one mature long bone; e.g., closed epiphyseal growth plate of the humerus).
    Dosing per FDA labeling for the indication requested.
    Authorization up to 12 months for initial requests.

    INITIAL THERAPY CRITERIA

    Typical initial dosing regimens discussed in clinical trials.

    Prolia dosing (osteoporosis, ADT-related bone loss): 60 mg subcutaneously every 6 months (Q6M).
    Xgeva dosing (prevention of skeletal-related events in metastatic cancer): 120 mg subcutaneously every 4 weeks (monthly).
    Products included under these renewal criteria: Bilprevda, Bomyntra, Osenvelt (preferred), Wyost (preferred), Xgeva, and Xbryk
    Line of business: Medicare and Medicaid (renewal approvals follow the stated approval length and documentation requirements)

    See indication-specific renewal sections for any additional required elements (for example, continued androgen-deprivation therapy for prostate cancer or continued aromatase inhibitor therapy for breast cancer)

    Renewal criteria — Renewal criteria common elements

    Common elements required for renewal of denosumab (all indications where renewal is applicable):

    ALL of the following

    • Documentation that member remains on the relevant systemic therapy associated with the original indication (e.g., androgen deprivation therapy for prostate cancer; aromatase inhibitor for breast cancer)
    • Clinical documentation of positive treatment response or continued clinical benefit since initiation (progress notes, imaging, laboratory results as appropriate)
    • Dosing and administration records demonstrating treatment consistent with FDA-approved labeling for the specific denosumab product requested
    • Authorization requests (initial and renewal) will be approved for periods up to 12 months per authorization; provider should request renewal annually as needed

    Documentation regarding prior bisphosphonate therapy (where required by indication)

    • Evidence of intolerance, contraindication (including significant renal insufficiency), or failure of intravenous bisphosphonate therapy (e.g., pamidronate, zoledronic acid) within the prior 30 days when the indication specifies this requirement
    • If the indication permits, documentation of prior oral bisphosphonate intolerance may be accepted when consistent with the specific initial criteria for that diagnosis

    Authorization length and administrative notes

    • Standard approval length for initial and renewal requests: up to 1 year (12 months). Providers should submit renewal requests with supporting documentation of continued benefit
    • Medicare Part B 90-day transition: for new Medicare members on an active course of denosumab, coverage and step-therapy requirements do not apply during the first 90 days after enrollment (refer to transition policy)

    Continuation interpretation from long-term data: FREEDOM extension post-hoc analyses demonstrated lower subsequent osteoporotic fracture incidence while continuing denosumab (up to 10 years) compared with placebo; this evidence may inform clinical decisions regarding ongoing therapy but renewal still requires the documentation elements above

    Denosumab and biosimilars — cancer indications: refer to the cancer-related indication groupings and required documentation for indication-specific renewal rules (header: Denosumab and biosimilars, Cancer Related Indications)

    Continuation data (FREEDOM extension) — Long-term extension data and interpretation regarding continuation of denosumab therapy

    Long-term continuation interpretation based on extension study data (FREEDOM extension):

    ALL of the following

    • Post-hoc FREEDOM extension data show a lower exposure-adjusted incidence of subsequent osteoporotic fractures for subjects continuing denosumab (combined denosumab up to 10 years) compared with placebo (hazard ratio 0.59, 95% CI 0.43–0.81; p=0.0012)
    • These extension data support that continued denosumab treatment may reduce risk of subsequent fractures versus discontinuation; however, continuation approvals still require the renewal documentation and authorization length limits stated in the policy
    ref
    title
    ref_value_replacement_for_schema_bug_fixing PLEASE_REMOVE_OR_IGNORE_THIS_LINE_DO_NOT_OUTPUT
    Prior Authorization

    Renewal requirements for ADT-associated bone loss

    Renewal requires the member to be receiving androgen deprivation therapy, to have documentation of a positive clinical response to therapy, dosing that is in accordance with FDA‑approved labeling, and authorization is limited to no more than 12 months.

  1. Coverage and Step Therapy suspended during active treatment in transition window
  2. Prior Authorization

    Authorization length: initial and renewal = 1 year

    Authorizations (initial and renewal) are required and approvals are issued for up to one year (authorization limited to no more than 12 months).

    • Approval length: Initial/Renewal Request = 1 year
    • Authorization required
    Step Therapy

    Formulary preference and step requirements

    Preferred agents may be approved when criteria are met. For non-preferred agents, the member must have tried and failed two preferred agents from each drug class (or one if only one preferred exists) before non-preferred approval.

    • Preferred agent approval permitted if criteria met
    • Non-preferred: trial/failure of 2 preferred agents per class (or 1 if only one preferred exists)
    Documentation Required

    Document prior IV bisphosphonate failure/contraindication/intolerance

    For several indications (e.g., hypercalcemia of malignancy, systemic mastocytosis, giant cell tumor of bone), documentation must show refractory (within the past 30 days), contraindication (including renal insufficiency), or intolerance to intravenous bisphosphonate therapy (e.g., pamidronate, zoledronic acid).

    • Refractory to IV bisphosphonates within past 30 days
    • Or documented contraindication (including renal insufficiency)
    • Or documented intolerance to IV bisphosphonates
    Billing Rule

    Dosing must follow FDA-approved labeling

    Dosing for denosumab must be in accordance with United States FDA–approved labeling for the specific indication.

    • Follow FDA-approved dosing per indication (e.g., Prolia 60 mg Q6M; Xgeva 120 mg monthly where applicable)
    Documentation Required

    Medicare Part B coverage context for outpatient administration

    Medicare may cover outpatient (Part B) drugs furnished 'incident to' a physician's service when the drugs are not usually self-administered; refer to Medicare Benefit Policy Manual, Chapter 15, Section 50 and applicable LCDs/LCAs for coverage details.

    • Part B coverage may apply when drugs are furnished 'incident to' and not usually self-administered
    • No NCD specific to denosumab; check applicable LCDs/LCAs
    Note

    Denosumab and biosimilars — cancer-related indications

    Denosumab (Xgeva) and listed biosimilars are addressed under the policy for cancer-related indications (prevention of skeletal-related events, giant cell tumor of bone, hypercalcemia of malignancy) and are subject to the authorization and clinical criteria in this section.

    • Indications include hypercalcemia of malignancy, giant cell tumor of bone, and prevention of SREs in metastatic disease
    • Products listed for cancer-related indications include Bilprevda, Bomyntra, Osenvelt (preferred), Wyost (preferred), Xgeva, Xbryk
    Prior Authorization

    Adoption notice: Optum Health guidance adopted

    The policy adopts Optum Health's 'Denosumab and Biosimilars, Cancer Related Indications' guidance (12/5/2025), which updated prior authorization criteria for cancer-related denosumab indications.

    • Change history: adoption of Optum Health guidance dated 12/5/2025
    Skeletally mature adolescent: has at least one mature long bone (e.g., closed epiphyseal growth plate of the humerus).
    Age criterionUsed as an alternative to '≥18 years' where specified in indications (e.g., giant cell tumor of bone).
    ApplicationApplies to indications that permit skeletally mature adolescents when adult dosing/indications are appropriate and surgical resection is infeasible or morbid.
    Hypercalcemia of malignancy — definition
    DefinitionHypercalcemia of malignancy defined as albumin-corrected serum calcium > 12.5 mg/dL (3.1 mmol/L).
    Prior therapy requirementRefractory (within the last 30 days), contraindication (including renal insufficiency), or intolerance to IV bisphosphonate therapy (e.g., pamidronate, zoledronic acid) is required for initiation.
    DosingDosing must follow FDA-approved labeling for hypercalcemia of malignancy.
    Denosumab / RANKL inhibitor
    MechanismMonoclonal antibody that binds RANKL, preventing activation of RANK on osteoclasts and osteoclast precursors, thereby decreasing bone resorption and increasing bone mass.
    Clinical effectInhibits osteoclast formation, function, and survival to reduce bone resorption and related skeletal pathology in malignancy and giant cell tumor of bone.
    Therapeutic usesUsed for osteoporosis, prevention of skeletal-related events in malignancy, treatment of unresectable giant cell tumor of bone, and hypercalcemia of malignancy refractory to bisphosphonates.
    Medicare Part B 'incident to' coverage
    DefinitionMedicare Part B may cover outpatient drugs 'incident to' a physician's service when the drugs are not usually self-administered by patients and are furnished as part of the physician's services (Medicare Benefit Policy Manual, Ch.15 §50).
    ContextDenosumab (Xgeva) is a Part B outpatient drug in settings where it is physician-administered; confirm 'incident to' criteria for billing and coverage.
    Operational noteFor new Medicare members, a 90-day transition period may exempt coverage and step therapy requirements if the member is on an active course of treatment.
    Prolia / Xgeva — denosumab formulations
    ProductsProlia (denosumab) — indicated for osteoporosis and increasing bone mass; Xgeva (denosumab) — indicated for prevention of skeletal-related events, giant cell tumor of bone, and hypercalcemia of malignancy.
    Formulation noteDifferent branded formulations (Prolia vs Xgeva) reflect distinct FDA-labeled indications and dosing regimens (e.g., Prolia 60 mg SC Q6M; Xgeva 120 mg SC monthly).
    BiosimilarsMultiple biosimilars correspond to Prolia/Xgeva reference products (examples listed in policy: Bildyos, Conexxence, Jubbonti, Ospomyv, Stoboclo; Xgeva biosimilars: Bilprevda, Bomyntra, Osenvelt, Wyost, Xbryk).
    Denosumab (and biosimilars) — cancer-related indications
    ScopeDenosumab and listed biosimilars are included for cancer-related indications (prevention of SREs, giant cell tumor of bone, hypercalcemia of malignancy) under Medicare/Medicaid prior authorization criteria.
    HCPCS codesPrimary HCPCS code for denosumab: J0897; biosimilar HCPCS examples in policy include Q5136, Q5157, Q5158, Q5159 and other Q-codes.
    Products referencedPolicy references branded products Prolia and Xgeva and multiple biosimilar prescribing information entries (policy adopted external guidance for cancer-related indications).
    Denosumab and biosimilars — referenced products
    Included productsDenosumab references include Prolia and Xgeva as well as numerous biosimilars (e.g., Jubbonti, Wyost, Ospomyv, Xbryk, Bildyos, Bomyntra, Conexxence, Bilprevda, Stoboclo, Osenvelt).
    Regulatory referencesPolicy cites multiple biosimilar prescribing information entries and adopts Optum Health guidance for cancer-related denosumab indications (Change History).
    Coverage implicationAdoption of external guidance informs updated prior authorization criteria and preferred biosimilar listings for Medicare/Medicaid.

    Outpatient administration under Medicare Part B may be furnished in an infusion/clinic setting 'incident to' a physician's service when drugs are not usually self-administered; ensure billing aligns with Part B rules for such settings.

    • Site of care: infusion center/office when furnished 'incident to' physician service
    • Confirm Part B billing rules and LCD/LCAs as applicable

    Document product and code for cancer-related denosumab requests

    Xgeva and other denosumab products (including Osenvelt and Wyost) are listed among preferred products for cancer-related indications; document product selection in the authorization request.

    • List of preferred and listed products appears in the policy's cancer-related section
    • Include product name and HCPCS/Q-code in PA submission
    Note
    Billing Rule

    Include appropriate HCPCS/Q-code on PA and claim

    Multiple denosumab products and biosimilars (denosumab J0897 and biosimilar Q-codes) are listed in the coding table; include the appropriate HCPCS/Q-code (e.g., J0897, Q5136, Q5157, Q5158, Q5159) on claims and authorization requests.

    • Examples: J0897 (denosumab), Q5136 (denosumab-bbdz), Q5157 (denosumab-bmwo), Q5158 (denosumab-bnht), Q5159 (denosumab-dssb)
    Billing Rule

    Map biosimilar product names to Q-codes on submissions

    Specify the biosimilar product and corresponding Q-code (e.g., denosumab-bmwo = Q5157; denosumab-bbdz = Q5136) when submitting prior authorization or claims to ensure correct processing.

    • Q5136 = denosumab-bbdz (Jubbonti/Wyost)
    • Q5157 = denosumab-bmwo (Osenvelt/Stoboclo)
    Billing Rule

    Include all applicable biosimilar Q-codes on PA/claims

    List the specific biosimilar HCPCS/Q-codes (e.g., Q5158 for denosumab-bnht, Q5159 for denosumab-dssb) on authorization requests and claims to match the product provided.

    • Q5158 = denosumab-bnht (Bomyntra/Conexxence)
    • Q5159 = denosumab-dssb (Ospomyv/Xbryx)
    Note
    Documentation Required

    Reference cancer-related criteria and ICD-10 codes in PA

    Xgeva and listed biosimilars are recognized in the policy's cancer-related indications; when requesting coverage, reference the cancer-related criteria and include supporting documentation as required.

    • Indications and ICD-10 mappings are provided in the cancer-related section
    • Attach relevant diagnosis codes and clinical documentation with PA
    Documentation Required

    Reference prescribing information and adopted guidance in requests

    Denosumab products (Prolia, Xgeva) and multiple biosimilars are cited with prescribing information; providers should reference relevant prescribing information and the policy when requesting coverage.

    • Policy cites multiple biosimilar prescribing information entries
    • Adoption of external guidance (Optum Health) reflected in change history